Skip to main content

Table 2 Activity of bortezomib in tumor models in vivo.

From: Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy

Cancer Activity MTD References
Multiple myeloma Decreased tumor growth and angiogenesis; increased survival 0.5 mg/kg IV twice weekly for 4 weeks LeBlanc et al [43], 2002
Adult T-cell leukemia Decreased or no effect on tumor growth 1.0 mg/kg IP twice weekly for 2 weeks Tan and Waldmann [19], 2002
Satou et al [44], 2004
Lung Tumor growth delay and decreased lung metastases 1.0 mg/kg PO once daily for 18 days Teicher et al [45], 1999
Breast Decreased surviving fraction of tumor cells 5.0 mg/kg IP once Teicher et al [45], 1999
Prostate Decreased tumor growth; decrease or no effect on angiogenesis 1.0 mg/kg IV weekly for 4 weeks, or q 72 hrs for 15 days Adams et al [13], 1999
Williams et al [46], 2003
Pancreatic Decreased or no effect on tumor growth and angiogenesis; increased or no effect on tumor apoptosis 1.0 mg/kg IV biweekly for 2 to 3 weeks, or weekly for 4 weeks or 0.25 mg/kg IP biweekly for 4 weeks Shah et al [24], 2001
Nawrocki et al [47], 2002
Bold et al [48], 2001
Head and neck Decreased tumor growth and angiogenesis 1.5 mg/kg IP 3 times per week for 3 weeks Sunwoo et al [17], 2001
Colon Decreased tumor growth and increased tumor apoptosis 1.0 mg/kg IV twice weekly Cusack et al [30], 2001
Melanoma Decreased tumor growth and angiogenesis; increased tumor apoptosis 1.25 mg/kg SC twice weekly for 5 weeks Amiri et al [49], 2004
  1. MTD = maximum tolerated dose; IV = intravenous; IP = intraperitoneal; PO = by mouth; SC = subcutaneous.